The antimicrobial activity of CP-62,993 against four Chlamydia trachomatis isolates was compared with those of erythromycin, clindamycin, and tetracycline. The MIC of CP-62,993 was 0.26 to 1.02 ,ug/mi for 100% inclusion inhibition and 0.031 to 0.063 ,ig/ml for 50% inclusion inhibition. With pharmacokinetic and antimicrobial studies demonstrating prolonged half-life and in vitro effectiveness, CP-62,993 may make possible a single, short-course treatment regimen for C. trachomatis infection.
Chlamydial infection is now recognized as the most common sexually transmitted bacterial disease in the United States, with an estimated annual incidence of 3 million to 5 million infected people (7, 10) . The diagnosis and treatment for genital chlamydial infections is frequently complicated by coinfection with several other sexually transmissible pathogens, including Neisseria gonorrhoeae and Ureaplasma urealyticum. Therefore, therapy should be administered with antimicrobial agents that have a broad spectrum of activity (2, 3, 6 controls consisted of RPMI 1640 medium without antibiotics.
After 48 h of incubation, three wells per dilution were fixed and stained with a fluorescein-conjugated monoclonal antibody to C. trachomatis (Syva Corp., Palo Alto, Calif.) (8) . The MIC was defined as the lowest concentration at which complete inhibition of inclusion formation was observed.
The remaining wells were passed and incubated for another 48 h in culture media without antibiotics (4) . The MBC was defined as the lowest concentration of antimicrobial agent preventing inclusion formation after passage (5) .
CP-62,993 exhibited antimicrobial activity similar to that of erythromycin against all chlamydial strains tested (Table  1) . Complete inhibition of inclusion formation was achieved with both antibiotics between 0.26 and 1.02 ,ug/ml for all strains tested except the L2 serovar. The MIC of tetracycline ranged from 0.06 to 0.51 ,ug/ml for all strains. Clindamycin was the least active antibiotic, with complete inhibition of inclusion formation at a concentration of 2 aLg/ml.
Endpoint titrations for the MICs of tetracycline, erythromycin, and CP-62,993 are shown in Table 2 . CP-62,993 exhibited in vitro activity similar to that of tetracycline at the 50% inclusion inhibition level (0.031 to 0.063 pug/ml). Erythromycin, however, showed 50% suppression between 0.125 and 0.51 ,ug/ml.
The MBCs of CP-62,993 and erythromycin for cervical isolates 3012 and 3014 were between 0.51 and 1.02 ,ug/ml (Table 1 ). The MBCs of tetracycline for those isolates were 0.13 and 0.51 ,ug/ml, respectively. CP-62,993 had an MBC of 1.02 ,ug/ml when assayed with serovar E; however, chlamyd- (2, 3, 6) . The results of this study concur with those of previous studies demonstrating complete suppression of three genital strains, with the exception of the L2 lymphogranuloma venereum strain, at readily achievable drug concentrations (<1.0 ,ug/ml) (4, 5) . Despite this in vitro activity, occasional treatment failures have occurred, primarily due to lack of compliance by the patient (3, 4, 6) . One additional problem with these antibiotics is that neither is recommended for the treatment of concurrent gonococcal infection (3) .
Initial in vitro and in vivo studies have demonstrated that CP-62,993 differs structurally from erythromycin by a methyl-substituted nitrogen at position 9A in the macrolide ring. Because of this structural difference, the spectrum, potency, half-life, and tissue distribution of CP-62,993 are also different from those of erythromycin. CP-62,993 was also shown to be significantly more effective (MIC, <0.031 to 0.25 ,ug/ml) than erythromycin against penicillinaseproducing N. gonorrhoeae in vitro (Ryan et al., 26th ICAAC).
After a 500-mg dose of CP-62,993 in vivo, the peak levels in serum are slightly lower than those achieved with erythromycin, but the concentrations of CP-62,993 in tissue are 400 times that achieved in serum. Because of high tissue affinity, the drug has a long half-life, with detectable concentrations in urine 7 to 14 days after a single dose. The mean peak concentration of CP-62,993 in serum was 0.37 ,ug/ml compared with 1.73 ,ug/ml for erythromycin, and the serum half-life of CP-62,993 was 7 h compared with 1.0 h for erythromycin (A. R. English, A. E. Girard, C. Cimochowski, J. Faiella, and J. A. Retsema, 26th ICAAC, abstr. no. 933, 1986) .
The results of this study indicate that CP-62,993 is also effective against C. trachomatis in vitro, with MICs similar to those of erythromycin and tetracycline. Clindamycin MICs were higher than those observed with the other three drugs, although within a range routinely achieved during in vivo administration (8 to 16 ,ug/ml). Clindamycin was tested in this study because it is often used in the treatment of pelvic inflammatory disease (9) .
It therefore appears on the basis of this and previous studies that CP-62,993 might be an effective antimicrobial agent against C. trachomatis as well as against other sexually transmissible pathogens. This drug may offer an alternative to other treatments as a one-drug regimen for the treatment of concurrent infections. The prolonged half-life and extremely high tissue levels indicate a regimen of one dose per day, as well as a shorter course of therapy, which might also result in greater patient compliance and convenience. With these advantages, clinical trials of this agent in men and women with chlamydial and gonococcal urethritis and cervicitis are now warranted.
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